{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:36:14Z","timestamp":1784874974075,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antipsychotic medications are effective treatments for schizophrenia (SZ) and bipolar I disorder (BD-I), but when presented with different treatment options, there are tradeoffs that individuals make between clinical improvement and adverse effects. As new options become available, understanding the attributes of antipsychotic medications that are valued and the tradeoffs that individuals consider when choosing among them is important.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A discrete-choice experiment (DCE) was administered online to elicit preferences across 5 attributes of oral antipsychotics: treatment efficacy (i.e., improvement in symptom severity), weight gain over 6 months, sexual dysfunction, sedation, and akathisia. Eligible respondents were aged 18\u201364 years with a self-reported clinician diagnosis of SZ or BD-I.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 144 respondents with SZ and 152 with BD-I completed the DCE. Of those with SZ, 50% identified themselves as female and 69.4% as White, with a mean (SD) age of 41.0 (10.1) years. Of those with BD-I, most identified themselves as female (69.7%) and as White (77.6%), with a mean (SD) age of 40.0 (10.7) years. In both cohorts, respondents preferred oral antipsychotics with better efficacy, less weight gain, no sexual dysfunction or akathisia, and lower risk of sedation. Treatment efficacy was the most important attribute, with a conditional relative importance (CRI) of 31.4% for respondents with SZ and 31.0% for those with BD-I. Weight gain (CRI\u2009=\u200921.3% and 23.1%, respectively) and sexual dysfunction (CRI\u2009=\u200923.4% and 19.2%, respectively) were adverse effects in this study that respondents most wanted to avoid. Respondents with SZ were willing to accept 9.8 lb of weight gain or &gt;\u200925% risk of sedation for symptom improvement; those with BD-I were willing to accept 8.5 lb of weight gain or a\u2009&gt;\u200925% risk of sedation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this DCE, treatment efficacy was the most important attribute of oral antipsychotic medications among respondents with SZ and BD-I. Weight gain and sexual dysfunction were the adverse effects respondents most wanted to avoid; however, both cohorts were willing to accept some weight gain or sedation to obtain better efficacy. These results highlight features that patients value in antipsychotic medications and how they balance benefits and risks when choosing among treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-024-06034-1","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T12:03:06Z","timestamp":1725969786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder"],"prefix":"10.1186","volume":"24","author":[{"given":"Michael J.","family":"Doane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Boeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Vass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cooper","family":"Bussberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemangi R.","family":"Panchmatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Sajatovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"6034_CR1","first-page":"638","volume":"39","author":"KR Patel","year":"2014","unstructured":"Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39:638\u201345.","journal-title":"P T"},{"key":"6034_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3810\/pgm.2005.02.1585","volume":"117","author":"JF Goldberg","year":"2005","unstructured":"Goldberg JF, Citrome L. Latest therapies for bipolar disorder. Looking beyond lithium. Postgrad Med. 2005;117:25\u20136, 29\u201332, 35\u20136. https:\/\/doi.org\/10.3810\/pgm.2005.02.1585","journal-title":"Postgrad Med"},{"key":"6034_CR3","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1517\/14656560903061309","volume":"10","author":"J Volavka","year":"2009","unstructured":"Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917\u201328. https:\/\/doi.org\/10.1517\/14656560903061309","journal-title":"Expert Opin Pharmacother"},{"key":"6034_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2147\/ppa.s270020","volume":"14","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Sajatovic M, Weiden PJ, O\u2019Sullivan AK, Maher S, Bjorner JB, Sikora Kessler A, Carpenter-Conlin J, Bessonova L, Velligan DI. Antipsychotic treatment experiences of people with schizophrenia: patient perspectives from an online survey. Patient Prefer Adherence. 2020;14:2043\u201354. https:\/\/doi.org\/10.2147\/ppa.s270020","journal-title":"Patient Prefer Adherence"},{"key":"6034_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12888-020-02767-x","volume":"20","author":"L Bessonova","year":"2020","unstructured":"Bessonova L, Velligan DI, Weiden PJ, O\u2019Sullivan AK, Yarlas A, Bayliss M, Baranwal N, Rychlec K, Carpenter-Conlin J, Doane MJ, et al. Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey. BMC Psychiatry. 2020;20:354. https:\/\/doi.org\/10.1186\/s12888-020-02767-x","journal-title":"BMC Psychiatry"},{"key":"6034_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, Kilambi V, M\u00fchlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JF. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research practices Task Force. Value Health. 2013;16:3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223","journal-title":"Value Health"},{"key":"6034_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1586\/14737167.2.4.319","volume":"2","author":"R Viney","year":"2002","unstructured":"Viney R, Lancsar E, Louviere J. Discrete choice experiments to measure consumer preferences for health and healthcare. Expert Rev Pharmacoecon Outcomes Res. 2002;2:319\u201326. https:\/\/doi.org\/10.1586\/14737167.2.4.319","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"Suppl 1","key":"6034_CR8","doi-asserted-by":"publisher","first-page":"i55","DOI":"10.1136\/qhc.0100055","volume":"10","author":"M Ryan","year":"2001","unstructured":"Ryan M, Bate A, Eastmond CJ, Ludbrook A. Use of discrete choice experiments to elicit preferences. Qual Health Care. 2001;10(Suppl 1):i55\u201360. https:\/\/doi.org\/10.1136\/qhc.0100055","journal-title":"Qual Health Care"},{"key":"6034_CR9","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2147\/ppa.s114172","volume":"10","author":"EG Katz","year":"2016","unstructured":"Katz EG, Hauber B, Gopal S, Fairchild A, Pugh A, Weinstein RB, Levitan BS. Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Prefer Adherence. 2016;10:2127\u201339. https:\/\/doi.org\/10.2147\/ppa.s114172","journal-title":"Patient Prefer Adherence"},{"key":"6034_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ppa.s151561","volume":"12","author":"D Ng-Mak","year":"2018","unstructured":"Ng-Mak D, Poon JL, Roberts L, Kleinman L, Revicki DA, Rajagopalan K. Patient preferences for important attributes of bipolar depression treatments: a discrete choice experiment. Patient Prefer Adherence. 2018;12:35\u201344. https:\/\/doi.org\/10.2147\/ppa.s151561","journal-title":"Patient Prefer Adherence"},{"key":"6034_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1176\/appi.ps.201400188","volume":"66","author":"B Levitan","year":"2015","unstructured":"Levitan B, Markowitz M, Mohamed AF, Johnson FR, Alphs L, Citrome L, Bridges JF. Patients\u2019 preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv. 2015;66:719\u201326. https:\/\/doi.org\/10.1176\/appi.ps.201400188","journal-title":"Psychiatr Serv"},{"key":"6034_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1176\/appi.ps.201300290","volume":"65","author":"MA Markowitz","year":"2014","unstructured":"Markowitz MA, Levitan BS, Mohamed AF, Johnson FR, Bridges JF, Alphs L, Citrome L. Psychiatrists\u2019 judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. Psychiatr Serv. 2014;65:1133\u20139. https:\/\/doi.org\/10.1176\/appi.ps.201300290","journal-title":"Psychiatr Serv"},{"key":"6034_CR13","doi-asserted-by":"publisher","first-page":"sgab046","DOI":"10.1093\/schizbullopen\/sgab046","volume":"2","author":"P McCrone","year":"2021","unstructured":"McCrone P, Mosweu I, Yi D, Ruffell T, Dalton B, Wykes T. Patient preferences for antipsychotic drug side effects: a discrete choice experiment. Schizophr Bull Open. 2021;2:sgab046. https:\/\/doi.org\/10.1093\/schizbullopen\/sgab046","journal-title":"Schizophr Bull Open"},{"issue":"suppl 1","key":"6034_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bdi.13333","volume":"25","author":"MJ Doane","year":"2023","unstructured":"Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with bipolar I disorder [abstract P125]. Bipolar Disord. 2023;25(suppl 1):101. https:\/\/doi.org\/10.1111\/bdi.13333","journal-title":"Bipolar Disord"},{"key":"6034_CR15","unstructured":"Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Gasper S, et al. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with schizophrenia. Presented at: Annual Schizophrenia International Research Society Conference. Toronto, ON, Canada; May 11\u201315, 2023."},{"key":"6034_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","volume":"79","author":"S Leucht","year":"2005","unstructured":"Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79:231\u20138. https:\/\/doi.org\/10.1016\/j.schres.2005.04.008","journal-title":"Schizophr Res"},{"key":"6034_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429\u201335.","journal-title":"Br J Psychiatry"},{"key":"6034_CR18","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","volume":"177","author":"CU Correll","year":"2020","unstructured":"Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, Du Y, Simmons A, Hopkinson C, McDonnell D, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177:1168\u201378. https:\/\/doi.org\/10.1176\/appi.ajp.2020.19121279","journal-title":"Am J Psychiatry"},{"key":"6034_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1017\/S1092852920001376","volume":"26","author":"S Yagoda","year":"2020","unstructured":"Yagoda S, Graham C, Simmons A, Arevalo C, Jiang Y, McDonnell D. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectr. 2020;26:383\u201392. https:\/\/doi.org\/10.1017\/S1092852920001376","journal-title":"CNS Spectr"},{"key":"6034_CR20","unstructured":"Kuhfeld WF, Tobias RD, Garratt M. Efficient experimental design with marketing research applications. SAS. [https:\/\/support.sas.com\/techsup\/technote\/mr2010d.pdf]. Accessed July 24, 2024."},{"key":"6034_CR21","unstructured":"Orme BK. Sample size issues for conjoint analysis. In: editors. Getting Started With Conjoint Analysis: Strategies for Product Design and Pricing Research, edition edn. Madison, WI: Research Publishers; 2019. pp. 57\u201365."},{"key":"6034_CR22","unstructured":"Bliemer MCJ, Rose JM. Working Paper. Confidence intervals of willingness-to-pay for random coefficient logit models. Institute of Transport and Logistics Studies; The University of Sydney. [https:\/\/ses.library.usyd.edu.au\/handle\/2123\/19176]. Accessed September 11, 2023."},{"key":"6034_CR23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1742-1241.2006.01044.x","volume":"60","author":"L Citrome","year":"2006","unstructured":"Citrome L, Stroup TS, Schizophrenia. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract. 2006;60:933\u201340. https:\/\/doi.org\/10.1111\/j.1742-1241.2006.01044.x","journal-title":"Int J Clin Pract"},{"key":"6034_CR24","doi-asserted-by":"crossref","unstructured":"Murphy JJ, Allen PG, Stevens TH, Weatherhead D. A meta-analysis of hypothetical bias in stated preference valuation. Working paper no. 2003-8. University of Massachusetts Amherst Department of Resource Economics. [https:\/\/scholarworks.umass.edu\/cgi\/viewcontent.cgi?article=1200&context=peri_workingpapers]. Accessed January 10, 2024.","DOI":"10.2139\/ssrn.437620"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06034-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-06034-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06034-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:04:24Z","timestamp":1726013064000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-06034-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6034"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-06034-1","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were carried out in accordance with the Declaration of Helsinki and were approved by the institutional review board of RTI International. Each participant provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MJD and HRP are or were employees of Alkermes, Inc., at the time of the study and may own stock\/options in the company. MB, CV, and CB are or were employees of RTI Health Solutions, a not-for-profit research institute that received funding from Alkermes, Inc., to conduct this study and collect the data used for this publication. LC consulted with Alkermes on this research and has served as a consultant for AbbVie\/Allergan, Acadia, Adamas, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, MedAvante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo\/Sunovion, Supernus, Teva, University of Arizona, Vanda, and Wells Fargo, and one-off ad hoc consulting for individuals\/entities conducting marketing, commercial, or scientific scoping research; and speaker for AbbVie\/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, and Teva and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and universities and professional organizations\/societies; owns stocks (small number of shares of common stock) in Bristol-Myers Squibb, Eli Lilly, J&J, Merck, and Pfizer purchased >10 years ago and has stock options for Reviva; and has received royalties\/publishing income from Elsevier (topic editor, <i>Psychiatry, Clinical Therapeutics<\/i>), Springer Healthcare (book), Taylor & Francis (editor-in-chief, <i>Current Medical Research and Opinion<\/i>, 2022-date), UpToDate (reviewer), and Wiley (editor-in-chief, <i>International Journal of Clinical Practice<\/i>, through end of 2019). MS consulted with Alkermes on this research and has served as a consultant to Janssen, Lundbeck, Neurelis, Otsuka, and Teva; has received research grants (within 3 years) from the US Centers for Disease Control and Prevention, International Society for Bipolar Disorders, National Institutes of Health, and Patient-Centered Outcomes Research Institute; has received royalties from Johns Hopkins University Press, Oxford Press, Springer Press, and UpToDate; and has prepared CME activities for the American Academy of Child and Adolescent Psychiatry, American Epilepsy Society, American Physician Institute (CMEtoGO), Clinical Care Options, Neurocrine, and Psychopharmacology Institute.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"605"}}